Considerations for AR-V7 testing in clinical routine practice

Although a number of patients suffering from prostate cancer respond initially to androgen deprivation therapy (ADT), the majority of patients will progress to metastatic castration resistant prostate cancer (mCRPC) over time (1). Within this stage of disease, different therapeutic options are available, e.g., novel hormonal therapies (NHT) like abiraterone and enzalutamide, taxane based chemotherapy as well as novel, more experimental treatments (e.g., PARP inhibition, PSMA targeted radionuclide therapy, etc.) (2). Nonetheless, virtually all tumors develop resistance mechanisms to the respective therapies. Thus, preemptive knowledge of likelihood of response to a certain type of treatment is of high clinical interest.